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myeloid malignancies
acute myeloid leukemias
Acute myeloid leukemias (AMLs) are clinically and molecularly
heterogeneous. AML blasts are clonal cell populations
originating from transformed hematopoietic stem cells, and
they typically show a maturation block at early stages of
myelopoiesis. About half of all AML harbor chromosomal
translocations creating leukemogenic fusion genes, which
involve kinases, transcription factors, and/or receptors. The
causes of AML are in most situations unknown. Some
patients may report a history of exposure to ionic radiation or
toxic substances such as benzenes. Patients treated with
alkylating agents and radiation therapy, notably survivors of
Hodgkin’s disease (HD), may develop secondary AML
after many years. Cancer survivors who received etoposide
or other podophyllotoxins may develop AML with aberrations
of chromosome 11q23, usually with a latent period of a few
years only. In elderly patients, myelodysplastic syndromes
(MDSs) may precede the development of frank AML by months
or years.
AML patients usually present with nonspecific complaints,
such as fatigue, bleeding (which may be particularly severe in
APL), or infections. Occasionally, the diagnosis is a chance
finding when peripheral blood smears are prepared for other
reasons. In monocytic leukemias, infiltration of skin and
particularly gums may be conspicuous. Isolated tumors
composed of AML blasts are known as chloromas.
The diagnosis of AML is made by morphological examination
of peripheral blood and bone marrow smears.
Immunohistochemistry (for example, myeloperoxidase stains)
helps to ascertain the myeloid characteristics of blasts rapidly.
Karyotype aberrations are of paramount prognostic importance,
and therefore cytogenetic and molecular analyses of malignant
cells in an experienced laboratory are essential. In contrast to
acute lymphoblastic leukemia (ALL), immunophenotyping is of
lesser diagnostic importance in AML. Diagnostic data are
comprised in the World Health Organization (WHO) AML
classification which has replaced the former French-American-
British (FAB) classification. Work-up should include
a thorough search for concomitant disorders. Diabetes, heart
disease, renal failure, severe neurological disorders, and other
conditions may influence the decision of whether a patient
will be fit for intensive curative treatment or not, particularly in
the elderly. Information on the family pedigree must be
obtained, specifically in patients who might qualify for
allogeneic bone marrow transplantation (BMT).
The prognosis of AML is distinctly linked to chromosomal
aberrations and particular molecular abnormalities. AML with
the translocation t(8;21), or with aberrations of chromosome 16
(often with marrow eosinophilia), and APL with the typical
translocation t(15;17) carry a good prognosis, as do AMLs with
a normal karyotype and mutations of the C/EBPa gene.
AMLs with complex chromosomal aberrations, with particular
chromosomal deletions, or with the frequent molecular
abnormalities in the FLT3 tyrosine kinase gene have an adverse
outcome. Prognosis is also linked to age with younger patients
faring much better than the elderly.
Treatment with curative intent comprises one to several
inpatient induction cycles of intensive chemotherapy, usually
combining an anthracycline and cytarabine. Patients with APL
or AML with excessive leucocytosis are emergencies calling
for immediate treatment, with the latter requiring leukapheresis.
Very frequent complications of induction chemotherapy are
systemic infections due to severe neutropenia (often septicemia
and including fungal infections), requiring broad-spectrum
antibacterial treatment or antifungal agents. Hematopoietic
growth factors given to hasten neutrophil recovery seem to be
safe with no increased risk of early AML relapse, but their
routine use remains controversial. Prevention or treatment of
bleeding due to severe thrombocytopenia requires platelet
transfusions. Neutropenic enterocolitis and mucositis are also
frequent. APL specifically responds to all-trans-retinoic acid
(ATRA), a differentiating agent, which in addition to inducing
APL remission considerably reduces the incidence of severe
coagulopathy. ATRA needs to be combined with chemotherapy
for optimal results. The drug may induce the ATRA syndrome
or the APL syndrome that is characterized by fever and
leakage of fluid into the extravascular space. Withdrawal of the
drug and steroids is the appropriate therapeutic measure to be
undertaken. AML remission status should be checked with
bone marrow examinations after each treatment cycle.
Complete remission is defined as the absence of
morphologically discernible leukemic blasts in the marrow and
return of peripheral blood counts to (near) normal values. In
all, 70%–80% of AML can nowadays be expected to obtain
remission upon induction. Patients responding early have the
best prognosis and usually receive one to two cycles of intensive
consolidation chemotherapy. Long-term maintenance
chemotherapy is used in some centers but not universally
accepted. Patients with AML in first remission are candidates
for allogeneic BMT provided a human leukocyte antigen
(HLA) -identical sibling is available as a donor. Exceptions
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to this rule are selected patients with good-risk AML (including
APL, AML with the t[8;21] or with aberrations of chromosome
16, as well as AML with a normal karyotype and a mutated C/
EBPa gene). High-dose chemotherapy with autologous stem-
cell transplants is still controversial and not routinely
recommended outside clinical trials. Refractory AML patients
have an adverse prognosis and may be candidates for
allotransplants with an unrelated HLA-matched donor, if found
within a reasonable period of time. Patients who are not fit for
intensive chemotherapy, particularly the elderly, should receive
supportive care including red-cell transfusions and low-dose
chemotherapy (such as hydroxyurea) to treat excess
leucocytosis. Platelet transfusions should be reserved for
bleeding episodes, since patients receiving repetitive platelet
transfusions may become refractory.
Prognosis and clinical outcome of AML vary with the type of
AML and most importantly age. Younger AML patients may
expect cure rates of up to 50%, whereas the average long-term
survival is 20%–25%. Good-risk patients, particularly APL,
may expect much better outcome with cure rates of 60%–70%.
Very few patients, who experience relapse, can be cured.
myelodysplastic syndromes
MDSs are chronic clonal hematopoietic malignancies mainly
seen in elderly patients. MDSs are derived from transformed
pluripotent hematopoietic stem cells, which give rise to
dysplastic and ineffective hematopoiesis in the marrow with
little output of mature blood cells into the periphery. Hence,
peripheral cytopenias result, often affecting erythroid, myeloid,
and platelet lineages. The causes of MDS are in most cases
unknown, but may be similar to those known for AML. Patients
usually present with slowly progressive clinical sequelae of
pancytopenia, and therefore may adapt well to anemia.
Likewise, a bleeding tendency due to thrombocytopenia may
insidiously increase over many months. MDS may enhance
symptoms of concomitant disorders such as coronary heart
disease or chronic obstructive pulmonary disease. Rare inherited
chromosome fragility states may be risk factor for MDS, as are
aplastic anemia and paroxysmal nocturnal hemoglobinuria.
Bone marrow and peripheral blood smear morphology are
cornerstones of a diagnosis of MDS. Bone marrow smears
should be stained for iron to detect ring sideroblasts in
refractory anemia. The diagnosis of MDS is not always easy
because morphological assessment of bone marrow pathology is
to some extent on the basis of the subjective judgment of the
hematologist. Reactive marrow alterations due to drugs or
vitamin-deficiency states should be excluded, either by
eliminating a suspect drug or by substitution of vitamin B12 or
folic acid. The detection of clonal chromosomal abnormalities
in a bone marrow karyotype may help to establish a diagnosis
of MDS. MDSs often show chromosomal deletions rather
than translocations, but their absence does not exclude the
diagnosis. The karyotype may show complex patterns, deletions
of chromosomes 7 and 5 [del(7q) and del(5q)] or of the Y
chromosome. In unclear situations, observation over time and
the examination of repeat marrow aspirates may greatly help.
Immunophenotyping and molecular genetics are not very
helpful in ascertaining the diagnosis of MDS. The FAB MDS
classification was modified by the WHO. MDSs comprise
a range of morphological marrow alterations from refractory
anemia with or without ring sideroblasts (indicating defects of
iron storage in the MDS clone) to refractory anemia with an
excess of blasts (RAEB) and finally RAEB transforming to frank
AML. Chronic myelomonocytic leukemia (CMML) has
traditionally been lumped together with MDS, but there is no
firm pathobiological basis for this. CMML typically shows
peripheral blood monocytosis (hence, tuberculosis must be
considered in the differential diagnosis) and an excess of
myeloid blasts in the marrow. MDS patients should also receive
a comprehensive work-up for concomitant disorders, which
are frequent in a typically elderly MDS patient population. In
the history, use of any kind of drugs (medical and other) should
be carefully sought after. The prognosis of MDS covers a wide
range from patients doing clinically well over many years to
patients who rapidly progress to treatment-refractory AML
shortly after diagnosis. An International Prognostic Scoring
System (IPSS) has been developed on the basis of the degree of
peripheral cytopenia, marrow blast counts, and karyotype
abnormalities [isolated del(5q) conferring an excellent
prognosis and patients with complex chromosome aberrations
faring very badly].
Treatment of patients with MDS is frustrating. Intensive
AML-type chemotherapy is much less effective in MDS, and
often fails to promote a return of polyclonal multilineage
hematopoiesis. Low-dose chemotherapy (e.g. low-dose
cytarabine) may occasionally improve peripheral cytopenias,
but often achieves deterioration of marrow function. The only
curative option is allogeneic BMT, but this is only available to
a small proportion of younger MDS patients with an HLA-
matched donor. In most patients, treatment is restricted to
supportive care. This comprises repetitive transfusions (which
may result in iron overload), antibiotics to treat infectious
episodes, and platelet transfusions (which should be limited to
clinically relevant bleeding episodes). In a subset of MDS
patients, demethylating agents, for example, 5-azacytidine, may
delay leukemic transformation and death. Hematopoietic
growth factors may transiently improve neutropenia
(granulocyte colony-stimulating factor) or anemia
(erythropoietin), but responses are inconsistent.
Patients with low-risk MDS according to the IPSS may expect
a median survival of 6 years (12 years in patients under the
age of 60), whereas high-risk patients rarely survive longer than
a few months to 1 year after diagnosis. About two-thirds of
MDS patients die because of their cytopenias, one-fourth
because of progression to AML, and one-fifth of patients die of
concomitant disorders.
chronic myeloid leukemia
Chronic myeloid leukemia (CML) is a model disorder among
the myeloproliferative syndromes with historic significance in
basic and clinical oncology research. It was the first human
malignancy to be linked to a specific recurrent chromosomal
aberration, t(9;22) also known as the Philadelphia chromosome.
The t(9;22) amalgamates two kinase genes, the ABL oncogene
and the BCR gene, to form a leukemogenic fusion gene
encoding a protein with aberrant tyrosine kinase function.
Annals of Oncology chapter 10
Volume 18 | Supplement 1 | January 2007 doi:10.1093/annonc/mdl452 | i55
Cloning of the BCR–ABL fusion gene and molecular analyses of
its role in leukemogenesis paved way to develop a small
molecule, imatinib mesylate (Gleevec or Glivec) blocking its
function, which epitomizes the principle of molecularly targeted
cancer therapy.
CML patients often exhibit few symptoms at presentation,
and the diagnosis is made by chance. Symptoms develop
insidiously and are mostly related to anemia and/or
splenomegaly. Splenomegaly is often the only pathological
clinical feature at presentation. Peripheral blood analyses show
anemia, and excess leucocytosis with all myeloid maturation
stages represented, and typically no maturation block. In
addition, thrombocytosis is a regular feature of CML in chronic
phase. The diagnosis is made by morphology of peripheral
blood films and bone marrow aspirates, where hypercellularity,
increased myelopoiesis, an increase in small (micro-)
megakaryocytes, and basophilia are typical.
Immunophenotyping is not particularly important, but the
detection of the Philadelphia chromosome either by classical
cytogenetics or by molecular analysis with a specific RT–PCR
assay (which is more rapid) is essential. Untreated CML may
persist in chronic phase for months up to many years, but
eventually progresses to blasts crisis with typical features of
AML, which is usually rapidly fatal. The blasts in blast crisis can
display myeloid or lymphoid markers or both, and additional
cytogenetic abnormalities are frequent. Prognostic scores for
CML patients such as the Hasford or Sokal scores all stem from
data collected in the pre-imatinib era and are therefore difficult
to extrapolate to present-day patients.
For many years, the standard treatment of chronic phase
CML was cytostatic drugs given to reduce excess leucocytosis,
such as hydroxyurea or busulfan. None of these ever resulted in
cure. Recombinant interferon-a with or without chemotherapy
provided a significant improvement, yielding not only
morphological but also cytogenetic complete responses, which
in turn convey a survival advantage. However, allogeneic
BMT or stem-cell transplantation in chronic phase was the only
therapy offering a chance of cure for many years. These
treatment strategies were partly overthrown when imatinib
mesylate (Glivec or Gleevec) was introduced. This small
molecule, a tyrosine kinase inhibitor, competitively blocks the
constitutional activity of the ABL kinase in the BCR–ABL fusion
protein which is crucial to CML pathogenesis. Side-effects of
imatinib mesylate are few, and remission rates in previously
untreated patients rank up to 95% (hematological), 80%
(cytogenetic), and 50% (molecular—using sensitive
quantitative BCR–ABL RT–PCR assays), respectively. Responses
take time, with maximum hematological responses seen at
approximately 6 months after start of treatment, and full
cytogenetic responses require three to six more months to
develop. Patients failing to respond or progressing under
imatinib now have an option to be treated with a newer
generation of small tyrosine kinase inhibitors, which may
overcome imatinib resistance. The combination of imatinib
mesylate with interferon-a or cytarabine seems to improve
results. Since no long-term results of imatinib mesylate are
available, definitive cure rates are unknown. It now is a challenge
to select appropriate CML patients for allogeneic
transplantation in chronic phase, given its much higher
morbidity and mortality compared with imatinib. Increasingly,
allogeneic transplants are restricted to CML patients with
suboptimal response to imatinib therapy. No substantial
progress has been made in the treatment of blasts crisis, where
the malignant cells are invariably treatment refractory and
outcome often rapidly fatal. Treatment algorithms have changed
in CML. Imatinib yields durable responses, an annual mortality
rate of only 1%–2%, and estimated median survival may rise
to become 10–15 years.
chronic myeloproliferative disorders
In addition to CML, polycythemia vera (PV), idiopathic
myelofibrosis (IMF), and essential thrombocythemia (ET) are
classified together with CML as chronic myeloproliferative
disorders (MPS). All are clonal disorders derived from
a transformed hematopoietic progenitor cell, but in contrast to
CML, and possibly PV (see below), no consistent diagnostic
cytogenetic or molecular markers have been described in either
IMF or ET. Recently, a mutation in the JAK2 gene has been
identified, occurring frequently in PV, ET, and IMF.
Clinically, PV often produces few symptoms. Erythrocytosis,
its hallmark, may lead to sluggish microcirculation and stasis
due to the increase in the hematocrit (HCT). Pruritus in the
legs, particularly after exposure to water (showering, etc.), may
be noteworthy in the patient’s history. Patients with PV show
a high risk of thrombosis and embolism, with arterial
thrombosis more common than venous thrombosis. PV is the
most common cause of hepatic vein thrombosis. On clinical
examination, the spleen is enlarged, and generalized erythema
may be conspicuous. On laboratory examination, erythrocytosis
and increase in the HCT are the leading findings. Their
differential diagnosis, which is not always easy, includes
many disorders leading to chronic tissue hypoxemia which
should be ruled out by measuring arterial oxygen saturation.
Unfortunately, there is no single easy diagnostic test to diagnose
PV with certainty. In vitro assays demonstrating erythroid
colony formation in bone marrow samples in the absence of
erythropoietin may help to rule out secondary causes of an
increased red-cell mass and establish clonal erythroid
proliferation characteristic of PV. Mutations of a tyrosine kinase
gene JAK2 (V617F) in myeloid cells have been linked with the
PV phenotype. Reliable and easily implemented methods for
detection of this mutation may revolutionize the way PV and
related disorders are diagnosed and classified. Traditionally,
treatment of PV is long-term repeated phlebotomy to induce
chronic iron deficiency and to reduce efficient erythropoiesis
in the marrow. A HCT of <45%–50% is a reasonable
treatment goal. Chemotherapy, particularly hydroxyurea, may
reduce excessive leucocytosis that can be a feature of PV.
Anticoagulants are necessary in patients with venous thrombosis
and platelet aggregation inhibitors in patients with arterial
thrombosis. Intensive chemotherapy has no role in PV, unless
patients progress to develop AML, which is rare. The role of
allogeneic BMT has not been defined, but it is sometimes
considered in very young patients.
IMF is the least common of all MPSs. IMF is a clonal stem-
cell disorder in the marrow with reactive extensive fibrosis of
bone marrow cavities, the molecular pathology of which is very
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poorly defined. Fibrosis in the marrow leads to extramedullary
hematopoiesis, particularly in liver and spleen, which are
typically enlarged, often to an extreme extent. Clinical
symptoms of IMF are non-specific. The peripheral blood films
show crowding out of erythroid and myeloid precursors,
a corollary of extramedullary hematopoiesis. Due to marrow
fibrosis, attempts at aspirating marrow mostly end with a dry
tap, and trephine biopsies must be obtained; they should be
stained specifically for fibrous tissue. There is no specific
diagnostic test to establish firmly a diagnosis of IMF, but the
diagnosis rests on a histology of diffuse bone marrow fibrosis,
the absence of the Philadelphia chromosome and a number of
minor criteria. IMF and its major complications, progressive
anemia, and splenic enlargement are difficult to treat.
Chemotherapy with hydroxyurea may reduce splenomegaly,
albeit transiently, as will therapy with interferon-a, at the cost of
its unpleasant side-effects. Splenectomy may be helpful to
improve the degree of cytopenias and to alleviate symptoms
caused by an enlarged spleen. A prognostic scoring system has
been developed, on the basis of the degree of anemia and the
white blood cell count and circulating blasts. The median
survival of good-risk patients may extend to 10 years, whereas
poor-risk patients (with marked cytopenias or marked
leucocytosis, etc.) fare much worse with median survival times
of 1–2 years only.
ET is a clonal hematopoietic stem-cell disorder, where
platelets are produced in excess without an appropriate
stimulus. The diagnosis is frequently made on routine
hematological analyses where platelet counts are incorporated.
Definitive diagnostic tests are unavailable, and causes of
secondary or reactive thrombocytosis must be ruled out. Due to
elevated platelet counts, arterial or venous thromboses, or
(paradoxically) spontaneous hemorrhage are typical clinical
complications of ET. Thrombocytosis per se is not a good
enough reason to start treatment, and no study has validated the
concept that lowering platelets in asymptomatic patients may be
of clinical long-term benefit. In patients having experienced an
arterial or venous thrombotic event, the usual principles of
treating thrombosis and embolism apply. If in this context,
lowering of the platelet count seems warranted, drugs such as
hydroxyurea, interferon-a, or anagrelide may be used. The latter
two have unpleasant side-effects, while hydroxyurea is
a mutagen, which is a special concern in these patients given
their usually long natural history.
lymphoid malignancies
acute lymphoblastic leukemia
In adults, ALL is much rarer than AML. The presenting features
are similar to AML, and include rapidly progressing malaise,
fever, as well as weight loss. Lymphadenopathy and hepato-
splenomegaly are more common than in AML. As in AML,
ALL can be a chance finding on a blood film in asymptomatic
patients. Clinical central nervous system (CNS) involvement
is uncommon at presentation, but may occur at relapse. ALLs
arise from malignant transformed stem cells committed to the
lymphoid lineage, and blasts are frozen at distinct early stages of
either B-cell or T-cell development. Chromosomal
translocations typically include antigen receptor genes as one
partner [immunoglobulin (Ig) heavy-chain genes in B-lineage
ALL and T-cell receptor genes in T-lineage ALL] juxtaposed to
an unrelated gene, mostly a transcription factor (such as the
myc oncogene) or a kinase. The single largest subgroup of adult
ALL patients are Philadelphia-chromosome-positive ALL,
unfortunately with a bad prognosis. The causes of ALL are
unknown, but in rare instances, previous exposure to radiation
may play a role. Chemicals and previous cancer therapy very
rarely induce secondary ALL. An uncommon human ALL, adult
T-cell leukemia, is closely linked to infection with HTLV-1,
a leukemogenic virus.
Morphological examination of blood and bone marrow is the
basis for diagnosis. Bone marrow biopsies are often needed,
as a fair number of patients show a packed marrow where
aspiration is impossible (dry tap). Immunophenotyping plays
a central role in defining clinically relevant subsets of ALL, such
as common B-precursor ALL (CALLA+ ALL), Burkitt-type
ALL, or T-ALL. Burkitt-type ALL must specifically be
recognized at diagnosis, since it requires separate treatment
protocols. This ALL entity mostly presents with impressive
hepato-splenomegaly, and the malignant cells exhibit
chromosomal translocations involving the myc oncogene on
chromosome 8, express surface Ig, but lack terminal deoxy-
transferase. Some acute leukemias co-express both lymphoid
and myeloid antigens. Such patients tend to have a poor
outcome regardless of whether they are treated along ALL or
AML protocols. As in AML, molecular genetics and cytogenetics
help to define prognostically distinct ALL entities. Philadelphia-
positive ALLs fare worst, whereas T-cell ALLs enjoy a much
better outcome. At work-up, important concomitant disorders
should be taken into account when a treatment plan is
established. Information on the family is important, since many
adult ALL patients might require allogeneic BMT in first
remission.
Induction treatment is geared toward obtaining complete
remission. Drug combinations include steroids, anthracyclines,
vinca-alkaloids, and alkylating agents, topped up with L-
asparaginase, and initial remission rates are in the order of 80%–
100%. Tumor lysis syndrome may complicate initial treatment,
particularly in patients with excessive leucocytosis. Once
remission is obtained, there are several options for continuing
treatment, but no ‘best’ protocol can be defined at present.
Remission consolidation with intensified chemotherapy aiming
at destroying minimal residual ALL uses drugs such as
methotrexate, cytarabine, given systemically and intrathecally
to prevent relapse in the meningeal sanctuary. In contrast to
AML, maintenance chemotherapy is still standard in many
institutions, although its value has occasionally been challenged.
Traditionally, combinations of methotrexate, 6-
mercaptopurine, and steroids are given in monthly cycles >1–3
years. Adult ALL patients are at a considerably higher risk of
relapse than children, and therefore many young to middle-aged
patients are candidates for allogeneic BMT in first remission,
particularly those with Philadelphia-positive ALL or precursor
B-cell ALL. The role of high-dose chemotherapy with
autologous peripheral stem-cell transplantation remains
unclear. Philadelphia-positive ALL should also receive imatinib
mesylate (Glivec) at some stage. Burkitt-type ALL or mature
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B-cell ALL should be treated with repetitive short intensive
chemotherapy cycles, and standard ALL protocols are
inadequate for this particular type of leukemia. In elderly
patients, where intensive treatment is not possible, maintenance
regimens may provide clinically satisfactory results with
remissions lasting for up to 1–2 years without excessive toxicity.
In summary, treatment protocols for adult ALL should aim
for risk-adapted therapy, and hence comprise complicated
algorithms to guide treatment choice through the different
phases the disease may take.
Adult patients with ALL generally fare much worse than
children. Although initial remission rates are high, most patients
will ultimately relapse with chemotherapy-refractory disease
and/or CNS involvement. The best prognostic entities of adult
ALL are Burkitt-type ALL and T-cell ALL with long-term cure
rates of 80%. Less than 30%–40% of patients with B-cell
precursor-type ALL survive for more than a few years, and
Philadelphia-positive ALL patients are not curable with
conventional chemotherapy. Their results may be improved by
early allogeneic transplantation in younger patients, and
possibly by adding imatinib mesylate (Glivec) to the
regimen. Older ALL patients usually survive for less than
a few years only.
chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most common
leukemia in the Western world and particularly affects
elderly patients. The disease results from accumulation of
clonal neoplastic relatively well-differentiated lymphoid cells
(mostly of B-cell lineage, rarely T cells) with deranged apoptosis
programs. The molecular pathology of CLL is characterized by
chromosomal deletions, rather than translocations. Although
many of these deletions have been mapped extensively, very
few genes have been defined that play a specific role in the
molecular pathology of CLL. Clinically and biologically CLL is
extremely heterogeneous, despite some common features. After
a long indolent clinical course, a minority of CLL patients
may transform to more aggressive lymphoid neoplasms,
including high-grade B-cell lymphoma (Richter’s syndrome).
CLL is more often associated with autoimmune phenomena
than any other leukemia, particularly immune
thrombocytopenia or autoimmune hemolytic anemia.
In many patients, the diagnosis of CLL is made by chance on
a peripheral blood count. A minority of patients are
symptomatic at diagnosis, mainly presenting with enlarged
lymph nodes or recurrent infections, for example, pneumonia
or sinusitis. Lymphocytosis on a blood film should reach levels
of 5000 lymphoid cells/ll or more for a diagnosis of CLL to
be considered, but even at these levels reactive lymphocytosis
must be carefully excluded. CLL cells may easily be damaged
when a blood smear is prepared, and appear as smudge cells or
Gumprecht cells. The most important diagnostic technique to
complement morphology is immunophenotyping. B-CLL
cells typically express B-cell markers such as CD19, CD20, and
CD23, but also CD5, a T-cell antigen. B-CLL cells are mature
enough to express surface Igs, albeit at low intensity.
Immunophenotyping data have been assembled into diagnostic
scores to differentiate CLL from other lymphoid neoplasms that
may release neoplastic lymphoid cells into the peripheral blood.
The bone marrow, usually examined at presentation, does in
fact not add very much essential information. In contrast to
all other leukemias, CLL patients require some staging similar to
lymphoma, since in addition to cytopenias, lymphadenopathy
and splenomegaly are criteria to separate CLL into stages with
distinctly differing prognoses (the Rai and the Binet staging
systems are still most commonly used). Chest X rays and
abdominal ultrasound or computed tomography (CT) scans
may therefore be helpful. In contrast to acute leukemias and
CML, cytogenetic analysis of CLL has not been widely
incorporated into routine, mainly for technical difficulties,
but it conveys important prognostic information. As an
alternative (if available), chromosomal deletions can be
detected by FISH using probes targeting loci of interest.
Patients with the relatively frequent deletion at chromosome
13q usually show an indolent course, whereas patients with
deletions within chromosome 17 or complex aberrations fare
poorly. A number of molecular techniques have become
available to break CLL into prognostically distinct subgroups.
Direct sequencing of Ig variable chain genes permits one to
assess CLL cells for IgV somatic hypermutation, which conveys
a much better prognosis than germline IgV genes. Surface
markers such as CD38 or ZAP70 may serve as surrogate
markers for the IgV gene status, if direct molecular analysis is
not possible.
CLL is usually responsive to a variety of chemotherapy
agents, but not curable. In early stage CLL, treatment is usually
deferred for months or often many years after diagnosis,
particularly in good prognosis subgroups. Patients with disease-
related symptoms or complications require treatment.
Alkylating agents, particularly chlorambucil, have long been the
standard front-line treatment, but in many centers have been
replaced by fludarabine, given its high remission rate and its
advantage in terms of progression-free survival. Treatment is
usually given to the point of maximum response, but should not
exceed half a year for fear of cumulative toxicity. Combination
chemotherapies usually fare no better than single-agent
treatment, but may be an option at second or third line. The best
use of monoclonal antibodies, particularly rituximab directed
against CD20 and CAMPATH-1H targeting the CD52
antigen, remains to be defined in CLL. High-dose chemotherapy
with autologous stem-cell transplantation cannot be
recommended in routine, and allogeneic stem-cell
transplantation is not often performed, since many CLL patients
are too old. Response criteria to assess treatment in CLL
have been defined by the National Cancer Institute Working
Group.
CLL patients with good prognostic features may live for
many years, often for long periods without any treatment at
all. The median survival for Rai stage 0 patients is 12 years.
Patients in adverse prognostic groups, e.g. far-advanced Rai
stages, or patients with adverse cytogenetic or molecular
markers (for example, IgV gene germline configuration) may
show an aggressive clinical course, often fatal within
1–2 years. Treatment and hence the prognosis of CLL are
likely to change during the coming few years, as the results of
many large trials on risk-adapted treatment are becoming
available.
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prolymphocytic B-cell leukemia
Prolymphocytic B-cell leukemia (PLL) is a rare disease of the
elderly, presenting with advanced-stage disease and an
aggressive course. It can be distinguished from classical B-cell
CLL by the distinct morphology of prolymphocytes on a blood
smear and by its immunophenotype, where in contrast to B-
cell CLL, CD5 is negative. Since PLL responds more poorly to
treatment than classical B-CLL, the prognosis tends to be
much worse.
hairy cell leukemia
Hairy cell leukemia (HCL) also needs to be considered in the
differential diagnosis of CLL and other lymphoproliferative
disorders with peripheral blood lymphocytosis. The typical HCL
patient is an elderly male with peripheral pancytopenia
(including notably monocytopenia), atypical lymphoid cells on
the blood smear that stain for tartrate-resistant acid
phosphatase, and splenomegaly. The immunophenotype shows
mature B-cell markers including CD45, a molecular involved
in B-cell or T-cell signaling, as well as CD25 (the IL-2 receptor),
but also the monocytic antigen CD11c. HCL usually runs an
indolent course, but because of marked pancytopenia, treatment
is often necessary. HCL shows an interesting ‘treatment history’.
It was one of the first disorders to be demonstrated to respond
to interferons, which, however, were overruled by the purine
analogues, particularly cladribine (2-chloro-deoxy-adenosine).
A single course of treatment very often brings about lasting
remissions. Splenectomy is nowadays reserved for the rare
patients with therapy-refractory disease who experience
complications of splenomegaly.
multiple myeloma, plasmacytomas, MGUs and
Waldenstro¨m’s macroglobulinaemia
Multiple myeloma (MM), extramedullary and solitary
plasmocytomas, monoclonal gammopathy of uncertain
significance (MGUS), and Waldenstro¨m’s macroglobulinaemia
(WM) are part of a spectrum of mature clonal B-cell neoplasms
where neoplastic plasmacytoid cells accumulate, and produce
and often (but not always) excrete a monoclonal Ig molecule
detectable on serum or urine immune electrophoresis as
monoclonal gammopathy or a paraprotein peak. Paraproteins
in MM are of the IgA, IgD, or IgG subclass, or may consist
exclusively of Ig light chains. WM by definition shows IgM.
Although no consistent genetic abnormality has been found in
either MM or WM, a number of karyotype abnormalities (for
example, deletions on the long arm of chromosome 13) are
found in MM.
Patients may present with symptoms, or the diagnosis may be
made by chance, when an excessively high erythrocyte
sedimentation rate (ESR) (due to the monoclonal serum
protein) is investigated, or when a serum electrophoresis is
commissioned for unrelated reasons. Monoclonal
gammopathies can occur in diseases other than MM, or WM,
particularly in B-cell CLL, indolent non-Hodgkin’s lymphomas
(NHLs), cold agglutinin disease, or amyloidosis. Symptoms
of MM or WM are quite distinct. MM tends to destroy bone,
and osteolytic lesions cause pain (particularly back pain) and
fractures, or there may be severe osteoporosis. Osteolytic activity
may lead to hypercalcemia. Ig paraproteins, particularly Ig k
or j light chains (also known as Bence-Jones protein), may
damage the kidney tubules, and renal failure is therefore
frequent. These features are uncommon in WM, where instead,
symptoms of anemia and particularly the hyperviscosity
syndrome due to hyperproteinemia and excess serum IgM
prevail. Erythrocyte transfusions to anemic WM patients may
trigger off a formerly silent hyperviscosity syndrome because of
an increase in intravascular red-cell volume on top of an
expanded plasma protein mass. Both MM and WM infiltrate the
bone marrow and lead to cytopenias. Extramedullary and
solitary plasmocytoma usually present as tumors in soft tissue
or associated with bone, respectively, with or without a
paraprotein detectable in the serum or urine.
In MGUS, the number of plasma cells in the bone marrow is
normal, and the paraprotein the only abnormality in the work-
up of such patients. The diagnosis of MM, WM, and related
disorders must be ascertained by biopsy. Often bone marrow
aspirates and biopsies are diagnostic, but in some patients
extramedullary tumor masses must be biopsied surgically, or
through CT scan-guided biopsy. The malignant plasmacytoid
cells in MM or the neoplastic cells with lympho-plasmacytoid
morphology in WM are usually easy to identify through the
microscope. Immune-electrophoretic analysis of serum and
urine (collected over 24 h) is essential to identify and quantify
the type of paraprotein, and initial measurements are ideal
markers for later assessment of treatment. Rarely, patients with
MM, however, fail to secrete paraproteins, and their diagnosis
can only be made by morphology. Increasingly, karyotype
abnormalities (detectable by FISH) have turned out to be of
prognostic value. For example, deletions of chromosome 13
imply an adverse outcome. Staging of MM usually requires an
assessment of the extent of bone involvement, either by
conventional X-ray imaging, CT scans, or magnetic resonance
imaging. Bone scans have a high false-negative rate and are
therefore not routinely recommended. The b2-microglobulin
(i.e. the light chain of the major histocompatibility complex) in
the serum is a helpful prognostic marker (provided the serum
creatinine is normal), and its increase indicates a large tumor
mass and an adverse prognosis. Traditional staging of MM (the
Durie–Salmon Staging System) is on the basis of the levels of
paraprotein, the degree of anemia, serum calcium levels, and the
extent of bone destruction. The presence or absence of renal
failure is added as an affix. A new International Staging System
(ISS) is being introduced, where serum b2-microglobulin,
serum albumin, platelet count, serum creatinine, and age
emerged as powerful predictors of survival. The new ISS is
simple, on the basis of easy to use variables, and increasingly
recommended for widespread use.
Treatment may be deferred in patients with asymptomatic
early stage myeloma until disease progression or symptoms
occur. However, MM patients presenting with symptoms, or
patients with advanced-stage MM at diagnosis, invariably
require therapy. Melphalan and prednisone have long been
standard treatment of MM, and are probably no less effective in
the long run than more toxic traditional standard dose
combination chemotherapy. Progress in the therapy for MM has
come with the introduction of the VAD induction regimen
(incorporating high-dose steroids and suitable for patients in
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renal failure), followed in responders by high-dose melphalan.
In MM, the benefit of high-dose chemotherapy with autologous
stem-cell transplantation is particularly well documented,
although it is not curative. Newer clinical data suggest that more
progress in MM is on the horizon with the advent (or
reintroduction in clinical medicine, as it were) of thalidomide
and bortezomib, both very active drugs. Their ‘best’ place in the
therapy for MM still needs to be defined more clearly, but
combinations of thalidomide and steroids hold more
therapeutic promise than classical VAD. Interferon was hailed
for some time as beneficial maintenance treatment, but since no
survival benefit could be found, enthusiasm for this toxic and
costly drug has dampened. Extensive osteolytic lesions in the
bone may require radiotherapy, or surgery to prevent or repair
pathological fractures. Osteolytic bone disease requires
supportive care with bisphosphonates, which inhibit osteoclast
activity. Bisphosphonates are the treatment of choice for
patients with MM-associated hypercalcemia and have largely
replaced calcitonin. Patients with MM and renal failure may
need renal dialysis.
Extramedullary and solitary plasmocytomas should be treated
with local radiotherapy, which often results in excellent long-
term control of the disease. The role of additional standard
chemotherapy in these particular patients is unclear, and the
newer agents active in MM have only scarcely been tested in
solitary plasmocytoma.
MGUS patients require no treatment, but regular follow-up
since some of them eventually progress to MM over many years.
The risk of transition from MGUS to frank myeloma is about
1% per year.
WM differs somewhat from MM in the treatment approach.
Plasmapheresis is often necessary in patients with excessive IgM
paraprotein to treat a symptomatic hyperviscosity syndrome.
Chemotherapy with alkylating agents (cyclophosphamide or
chlorambucil) and steroids has long been the standard
treatment; more recently, it has been replaced by first-line
fludarabine (particularly in the United States). The role of
high-dose melphalan has been much less well defined in WM
than in MM.
The prognosis of MM depends on the stage at presentation
and on a number of cytogenetic features (e.g. deletions of
chromosome 13). Patients at early stages may live up to
a median of several years, whereas patients with far-advanced
disease and adverse prognostic factors may survive for <1 year.
Prognosis in WM is better in that the median survival for most
patients is 5 years. Patients with extramedullary or solitary
plasmocytoma show a remarkably low local relapse rate after
radiotherapy, but many of them eventually progress to frank
MM after a median lag time of several years.
the malignant lymphomas
The malignant lymphomas are the largest group of
hematological malignancies. The vast majority are B-cell Non
Hodgkin’s lymphomas (NHL), followed by Hodgkin’s disease
(HD), and more rarely T-cell NHLs. Nodal NHLs are more
frequent than extranodal NHLs, with the latter group most
prevalent in the gastrointestinal tract, the brain and bone, as
well as skin. Lymphomas are clonal neoplastic proliferations
derived from transformed lymphoid cells. Virtually each stage
of lymphoid maturation, from early lymphoid precursor cells to
mature plasma cells, is represented by a particular type of
lymphoid neoplasm. Early lymphoid precursor cells give rise to
lymphoblastic lymphoma or ALL. Many NHLs are derived
from germinal center lymphoid cells, notably follicular
lymphoma or diffuse large B-cell lymphoma. Finally, myeloma
and WM are the malignant counterparts to plasma cells, which
have reached the final B-cell maturation stage. The cell of
origin of HD has long been elusive, but is now thought to
represent a transformed lymphoid B cell. Most NHLs exhibit
chromosomal translocations that are crucial for their molecular
pathology. In contrast to leukemias, translocations in NHL
usually do not form fusion genes but rather misplace an
oncogene present on one partner chromosome into the vicinity
of the promoter of a gene residing on the other chromosome.
Typically, that latter gene is actively transcribed in lymphoid
cells. In B-cell neoplasms, the promoter is usually derived from
an Ig gene, whereas in T-cell neoplasms, a T-cell receptor
gene promoter is used. Oncogenes placed under the influence of
these promoters are, for example, the c-myc gene (a
transcription factor) in Burkitt’s lymphoma (BL), a cyclin gene
(involved in cell cycle regulation) in mantle cell lymphoma,
the BCL-6 gene (a transcription factor active in germinal
centers) in diffuse large B-cell lymphoma, or the BCL-2 gene
(encoding a protein important for regulating programmed cell
death) in follicular lymphoma. Extranodal lymphomas
derived from transformed B cells in the mucosa-associated
lymphoid tissue (MALT lymphomas) are an exception to this
rule, since they show fusion genes similar to leukemias.
In patients with suspicious lymphadenopathy, a diagnostic
biopsy should be obtained before lengthy staging procedures are
undertaken. The diagnosis of a lymphoma requires sufficient
fresh tumor material. A fine-needle aspirate or a cytological
examination is usually not sufficient for definitive lymphoma
typing. The basis of lymphoma diagnostics is still morphology of
histological sections, complemented by immunohistochemistry
(many diagnostic antibodies can be used on formalin-fixed
material). Molecular analyses usually require fresh lymphoma
tissue, and include immunogenotyping to look for antigen
receptor gene rearrangements (to assess clonality) and the
detection of typical chromosomal translocations through
amplification of specific chromosomal breakpoints by PCR.
FISH can be applied for the same purpose. The diagnosis of
lymphoma requires an expert hemato-pathologist with special
training in this difficult field, and cannot be left to all-round
pathologists. The histopathological classification of lymphoma
has been a subject of much debate over many years, with
controversies between experts at times creating more confusion
than light. The taxonomical chaos has largely been overcome
with the introduction of the revised European–American
lymphoma classification, later amended and issued as the
current WHO classification of lymphoid neoplasms. It
incorporates histology, immunophenotype data, cytogenetics,
and molecular diagnostics to define distinct lymphoma entities
with clinical relevance. At the clinical level, NHLs are often
lumped as indolent (e.g. follicular lymphoma and other NHLs
with a long natural history), intermediate-grade [diffuse large
B-cell NHL (DLBCL), mantle cell NHL, and others], and truly
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high-grade NHLs (chiefly BL and lymphoblastic lymphoma).
DLBCLs are sometimes also referred to as ‘high-grade’ rather
than ‘intermediate-grade’ NHL.
Once the diagnosis of lymphoma is established, patients
require staging and a search for risk factors before treatment
decisions are made. An exception are patients with particularly
aggressive advanced lymphoma types (such as BL) or patients
with lymphoma involving critical anatomical sites, such as
patients with spine compression or the upper vena cava
syndrome. They may require immediate treatment, before
routine staging can be completed. Staging consists of a careful
clinical examination to detect the extent of lymphadenopathy,
as well as hepato-splenomegaly, and involvement of Waldeyer’s
ring. In the history, B symptoms (weight loss, unexplained
fever, and night sweats) should be specifically recorded. The
standard of imaging is still CT scanning, with positron emission
tomography increasingly gaining ground. In many lymphomas,
a bone marrow aspirate and biopsy are considered
compulsory to rule out marrow involvement. Sensitive PCR
assays to look for minimal occult marrow involvement cannot
be recommended as routine procedure. Since extranodal
lymphoma may simultaneously present in Waldeyer’s ring as
well as in the upper gastrointestinal tract, patients with
clinical involvement of Waldeyer’s ring require a gastroscopy
and vice versa. NHLs are classified according to the Ann
Arbor system that extends from stage I (involvement of one
lymph node area only) to stage IV (systemic disease with
involvement of extranodal tissue or organs). Gastric NHLs
are classified according to the Blackledge Staging System,
where stages I–III describe lymphoma limited to the
gastrointestinal tract with progressive degrees of loco-regional
penetration, and stage IV refers to disseminated disease.
Specific clinical features and treatment of different NHLs are
discussed below.
indolent lymphomas
Indolent (or ‘low-grade’) nodal B-cell NHLs include follicular
lymphoma, small lymphocytic lymphoma (which only differs
from B-CLL by exhibiting no particular propensity to spill
lymphoid cells into the peripheral blood), and marginal zone
lymphoma (which may also present at extranodal sites).
Follicular lymphomas (the most frequent subgroup of
indolent lymphomas) arise from germinal center B cells. More
than 90% of follicular lymphomas show the translocation
t(14;18) which juxtaposes the bcl-2 oncogene next to an Ig
heavy-chain gene promoter. On histology section, these
lymphomas should be graded according to the number of
lymphoid blasts present (grade 1–3). Patients often have few
symptoms, and typically consult a doctor because they
themselves have detected waxing and waning lymphadenopathy.
In a few patients, B symptoms provide the motif for further
clinical investigation. Bone marrow involvement at diagnosis is
frequent, but a minority of patients show extensive bone
marrow infiltration with clinical sequelae of cytopenias. An
International Prognostic Index (IPI) validated in diffuse large
B-cell lymphoma (see below) has been adapted to follicular
lymphomas to become FLIPI, on the basis of the same
parameters plus the hemoglobin level.
In early stage follicular lymphoma, radiotherapy to involved
sites is considered as a long-established standard, with
a potential for cure or at least long-lasting remission. In most
situations, chemotherapy is not recommended, except perhaps
for younger patients with adverse prognostic factors, and in
patients with grade 3 follicular lymphoma. Optimal treatment
choices for patients at advanced stages remain controversial.
The common denominator is that today virtually no treatment
is truly curative. In patients with few symptoms, in elderly
patients, and in patients with stable or slowly progressive
disease, therapy may be withheld for many months or
sometimes years, and the natural history may be very indolent.
General symptoms, progressive lymphadenopathy or
splenomegaly, or cytopenias are the main reasons for
administering therapy, but the ‘best choice’ is a matter of debate.
No survival advantage can be demonstrated when various
single-agent or combination chemotherapies are compared.
Typical first-line compounds include alkylating agents,
anthracyclines, purine analogues, steroids, and various
combinations thereof. In grade 3 follicular lymphoma, it seems
advisable to administer combination regimens typically used
in intermediate- to high-grade lymphomas. ‘Classical’
chemotherapy may be complemented by interferon (either
concomitantly or to maintain remission), but this is not
universally accepted. The addition of an anti-CD20 antibody,
rituximab, to chemotherapy increases remission rates, but more
importantly it may prolong survival, and is therefore
increasingly considered as an adjunct. Conjugated radioactive-
labeled antibodies are effective with acceptable non-
hematological toxicity profiles, and their use can be considered,
provided that the degree of bone marrow infiltration is low.
However, their place in clinical routine still needs to be
established. Patients in lymphoma relapse may be re-treated
with a previously used regimen, if the treatment-free interval is
long enough (at least a year as a rule of thumb), or they may
be treated with different combinations of cytostatic drugs,
topped up with rituximab. The remission duration between
second-line to later treatments progressively decreases by about
half after each additional regimen used, until patients become
truly therapy-refractory. In relapsed follicular lymphoma,
radiation therapy is often valuable if progressive tumor causes
local problems such as compression of vital anatomical
structures. The role of high-dose chemotherapy with autologous
stem-cell transplantation in follicular lymphoma is a matter
of much debate, mostly because few data from suitably sized
phase III trials are available. In first remission, its role has not
been established. In relapse, it should be considered (if at all)
before patients are heavily pre-treated, since results tend to be
better and toxicity more acceptable. In vitro purging of
harvested stem cells has not consistently been shown to provide
a clinical advantage. In younger patients with advanced
lymphoma and an HLA-identical sibling, allogeneic stem-cell
transplantation, perhaps using non-myeloablative regimens,
can be discussed. Its proper role is uncertain, but perhaps
its best place is at consolidation when lymphoma mass
reduction has been achieved with other means. In early stage
FL, two-thirds of patients may still be alive and well at 10
years, and one-third at 20 years of follow-up. Advanced FL
patients experience median disease-free survival of one to
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several years, and long-term survivor rates are in the range of
10%–20%.
Patients with small lymphocytic B-cell lymphoma (SLBL)
typically present with asymptomatic lymphadenopathy, and
often have bone marrow involvement, as well as lymphocytosis
in the periphery. If so, the separation of small lymphocytic
lymphoma from B-cell CLL becomes somewhat blurred. No
single typical chromosome or molecular abnormality has been
described in this lymphoma. A paraprotein peak may be present,
but usually less abundant than that in myeloma. The same
treatment recommendations specified for follicular lymphoma
or CLL apply. The clinical course of SLBL may be very slow and
indolent over many years, and therefore these patients should
be managed very conservatively and often must be convinced
that observation rather than treatment is in their best interest.
Marginal zone B-cell lymphoma has a particular propensity to
present extranodally, although nodal lymphoma is also well
known. The marginal zone corresponds to the outer limit of the
splenic white pulp and plays a critical role in the immune
response to T-cell-independent antigens. Many cases of splenic
lymphoma belong to this lymphoma type. Nodal marginal zone
NHL may develop in patients with preexisting autoimmune
inflammatory disorders, for example, Sjo¨gren’s syndrome.
Extranodal types of marginal zone NHL comprise the MALT
lymphomas and are discussed below. Patients with nodal
marginal zone NHL may be treated (or rather not treated!)
along the guidelines explained for the other subtypes of indolent
lymphoma. In patients with splenic lymphoma (presenting
with splenomegaly without lymphadenopathy), splenectomy is
often performed and is only for diagnostic purposes. Unless
specific clinical reasons are present, such patients usually do not
require further treatment. Vaccination against pneumococcal
infection is a must before splenectomy.
intermediate-grade NHL
Diffuse large B-cell lymphoma, grade 3 follicular lymphoma
(see above), immunoblastic NHL, and to some extent
mantle cell NHL can clinically be grouped together as
intermediate-grade NHL.
Diffuse large B-cell lymphoma (DLBCL) is most prevalent.
DLBCL often arise from transformed germinal center B cells,
but gene expression profiling suggests that a prognostically
distinct group of DLBCL may be derived from activated B cells.
The BCL-6 oncogene is often involved in chromosomal
translocations or otherwise mutated in germinal-center-derived
DCBCL. BCL-6 is transcriptional repressor, which is crucial to
the normal development of germinal centers in lymph nodes.
Patients with DLBCL may present (at different age groups) with
a wide spectrum of clinical problems, ranging from a single
enlarged painless lymph node to severe systemic illness with
rapidly progressive organ failure, for example, due to
compression of vital structures such as ureters or bile ducts.
Constitutional symptoms (B symptoms) may be pronounced.
Patients should be tested (with their consent) for HIV infection,
since lymphomas in HIV-positive patients often correspond
to this category. The IPI separates patients into distinct
prognostic categories. It uses simple factors including age (<60
years versus older), Ann Arbor stage I or II versus III or IV,
performance status (0 or 1 versus worse), lactate dehydrogenase
(LDH) (normal versus high), and the number of extranodal
sites (none/one versus more). Regardless of stage at presentation
and in contrast to indolent NHLs, immediate systemic therapy
is almost always warranted in DLBCL. In early stages, short-
term chemotherapy is customarily topped up with involved-
field radiotherapy, which improves local control and survival.
Longer chemotherapy may yield the same results, obviating the
need for local radiation. In advanced disease, front-line
chemotherapy typically consists of combinations of alkylating
agents, anthracyclines, vinca alkaloids, and steroids (CHOP or
CHOP-like regimens). More recent data suggest that the
addition of rituximab, an anti-CD20 antibody, improves results
and is therefore mandatory. Customarily, six to eight cycles
of systemic therapy are given to obtain and consolidate
complete remission. In advanced-stage lymphoma,
radiotherapy to areas of excessive tumor bulk can be discussed
as an adjunct to chemotherapy, for example, in mediastinal
sclerosing B-cell lymphoma. The role of consolidation high-
dose chemotherapy and autologous stem-cell transplantation in
first remission is still a matter of much debate, even in poor-risk
patients. Patients in relapse, however, who exhibit chemo-
sensitive disease, should receive high-dose chemotherapy. In
elderly patients, the feasibility of intensive treatment is often
limited, and prognosis therefore less favorable. Cure rates in
DLBCL are generally high approaching 80%–90% in patients
with favorable limited-stage disease, and hovering 50%–60%
in patients with advanced stages.
Patients with mantle cell lymphoma are mostly elderly males
who present with advanced disease, splenomegaly, and bone
marrow involvement. The neoplastic cells arise from
transformed B cells present in the mantle zone surrounding
germinal centers in lymph nodes. Mantle cell lymphoma often
shows a translocation t(11;14) joining the bcl-1 or cyclin D1
gene to the Ig heavy-chain gene promoter. Overexpression of
cyclin D1 can be assessed immunohistochemically. Therapy
guidelines in practice do not differ much from those
outlined for DLBCL, but the literature is somewhat more
controversial, and cure in this specific entity is rare.
Median overall survival is about 3 years, and median
response duration is typically short, usually in the range of
8–9 months.
aggressive NHL
Truly high-grade aggressive lymphomas include Burkitt’s and
Burkitt-like NHL [BL], as well as lymphoblastic lymphoma.
Concordance between pathologists in differentiating BLs from
Burkitt’s-like lymphoma on histological examination is low. BLs
are B-cell neoplasms characterized by rearrangements of the
c-myc oncogene, which is sometimes used to separate them
from BL-like lymphomas, but this is not quite clear. The
epidemic form of BL found in Africa is associated with chronic
Epstein–Barr Virus (EBV) infection, but in the Western World,
we see the so-called sporadic BL, which is not necessarily
linked to EBV. BL patients are typically young adult males, and
often present with rapidly progressive widespread disease and
at times impressive tumor bulk. Therapy differs from DLBCL.
It is on the basis of pulses of high-dose systemic combination
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chemotherapy including methotrexate and cytarabine at doses
which penetrate the cerebrospinal fluid. Transplantation is
advocated early, i.e. shortly after an initial response to
chemotherapy.
Lymphoblastic lymphoma is mostly identical to the T-cell
variant of ALL. Young adults are mostly likely to be afflicted,
and stage at presentation is usually advanced. It should be
treated in the same way as ALL (see above).
In highly aggressive NHL (including cases of advanced
DLBCL), chemotherapy may initially lead to very rapid and
substantial tumor destruction (tumor lysis syndrome).
Hyperuricemia, hypocalcaemia, hyperkalemia,
hyperphosphatemia, and metabolic acidosis are typical, and
renal failure is a real threat. Generous hydration, and
suppression of uric acid formation with allopurinol or
rasburicase, and at times renal dialysis are essential to overcome
this early complication of therapy.
T-cell NHL
Peripheral T-cell lymphoma is rare. The term refers to
a heterogeneous group of T-cell neoplasms that arise from
postthymic mature T-lymphoid cells, which must be
distinguished from immature or thymic T-cell neoplasms, for
example, T-cell lymphoblastic lymphoma or T-cell ALL.
Peripheral T-cell lymphomas include mycosis fungoides, which
predominantly involves the skin, but spreads to lymph nodes or
other organs at later stages. Rare (at times ill defined) entities
are angioimmunoblastic T-cell lymphoma, hepato-splenic
T-cell lymphoma of the a˜b- or the c˜d type, angiocentric T-cell
lymphoma, and others. T-cell lymphomas often present with
systemic symptoms, that may be severe, and with inflammatory
tissue alterations, such as skin vasculitis, granulomas in various
organs, lung infiltrates. The diagnosis is often very difficult, both
clinically and histologically. Once it is established, staging
procedures are performed as in the B-cell lymphomas. Few trials
exist to establish optimal treatment. Usually, T-cell lymphomas
are treated according to the guidelines established for
intermediate-grade B-cell NHL, but obviously without
rituximab, since T-cell NHLs do not express any CD20.
Many patients with T-cell lymphomas have a very poor
outcome, with the notable exception of patients with mycosis
fungoides, where disease may be limited to the skin for many
years and responds well to treatment (even if not curative in
the long run).
extranodal NHL
The management of extranodal lymphomas requires special
considerations. The three most frequently involved sites of
extranodal NHL are the gastrointestinal tract, the skin, and
the brain.
In patients with non-bulky early stage gastric MALT
lymphoma, antibiotics suitable to eradicate Helicobacter pylori
infection may suffice to induce lymphoma remission. Restaging
gastroscopy is required to document that H. pylori infection
has been eliminated and lymphoma has significantly regressed.
The role of chemotherapy in these patients has not been
established. In patients with advanced MALT lymphoma, the
same strategies of selecting treatment (or not) apply as for
advanced indolent nodal NHL. High-grade gastric MALT
lymphomas are usually treated with same regimens used in
intermediate-grade nodal NHL, followed by local radiation.
This approach has largely replaced surgery and conserves gastric
function. Patients with long-standing gluten-sensitive celiac
disease are at risk of developing enteropathy-type T-cell
lymphoma, which carries a poor prognosis despite aggressive
chemotherapy.
Primary cutaneous lymphomas often pose difficult diagnostic
problems, since chronic inflammatory skin lesions may mimic
clonal lymphoma. At least half of indolent B-cell lymphomas
of the skin do not spread to other organs and show a benign
clinical behavior, often obviating the need for therapy. Extensive
lesions can be controlled by local radiation if necessary.
Cutaneous T-cell lymphomas mostly present as the Se´zary
syndrome or mycosis fungoides (see T-cell lymphomas). Large
T-cell lymphomas may be CD30+ with a favorable prognosis,
or CD30 with a poor outcome.
Primary CNS lymphomas (virtually always of B-cell origin)
are most often seen in men in their fifties or sixties. A biopsy
should preferably be obtained before patients are given steroids,
since rapid response may obscure a histological diagnosis. The
histology almost always corresponds to a DLBCL type of
lymphoma. Systemic high-dose methotrexate has become
established, since it penetrates the blood-brain barrier, as does
high-dose cytarabine. The sequential use of high-dose
chemotherapy followed by radiation may perhaps improve
outcome, although it is often not well tolerated.
lymphoma and immunosuppression
Severely immunosuppressed patients, notably patients with
active HIV infection and organ-transplant recipients, are
particularly prone to developing lymphoma, mainly B-cell
lymphoma, presenting either as nodal lymphoma or as CNS
lymphoma. In HIV-positive patients, histology almost always
indicates intermediate- to high-grade disease, usually at an
advanced stage in nodal NHL. Organ-transplant recipients
under immunosuppression may show posttransplant
lymphoproliferative disease evolving through different steps
ranging from early polyclonal B-cell proliferation to full-blown
malignant monoclonal high-grade B-cell lymphoma. The same
treatment recommendations outlined for immunocompetent
NHL lymphoma patients would apply, but the feasibility of
intensive chemotherapy regimens is often jeopardized by an
excessive risk of infectious complications. In HIV-positive
patients, highly active anti-retroviral therapy is mandatory in
parallel with chemotherapy. In organ-transplant recipients,
immunosuppression should be tailored down to the minimum
level required to guarantee proper functioning of the
transplanted organ. In patients with posttransplant
lymphoproliferative disease, which has not yet fully progressed
to the point of becoming a monoclonal malignant lymphoma,
this important measure may suffice to induce remission.
Unless the degree of immunosuppression can be successfully
reduced, and full treatment given, the prognosis of these
patients is poorer than that in their immunocompetent
counterparts.
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Hodgkin’s disease
HD is traditionally discussed separately from the NHLs, since
HD entails a fair number of specific aspects, both in terms of
biology and treatment. The cell of origin is most likely to be
a transformed B cell. No consistent chromosomal or molecular
abnormalities have been described in HD, but deletions of
genetic material seem to be much more frequent than
chromosomal translocations. On histological examination, the
separation of nodular lymphocyte-predominant Hodgkin’s
lymphoma (NLP-HD) from classical Hodgkin’s lymphoma is
essential. The latter is split into the frequent nodular-sclerosis
and the mixed-cellularity subtypes, while lymphocyte-rich
classical HD is rare. Many cases formerly classified as
lymphocyte-depletion HD can nowadays be identified as NHL,
particularly T-cell NHL and T-cell-rich B-cell NHL, or
undifferentiated carcinomas, although true lymphocyte-
depletion HD patients do exist. Histologically, lesions contain
the pathognomonic Reed–Sternberg cells in classical HD, and
atypical B cells (‘popcorn cells’) in NLP-HD. Staging procedures
in HD are not much different from NHL. Staging laparotomy
with splenectomy has been abandoned, since it provides no
clinical advantage over modern imaging. In contrast to NHL,
HD spreads via neighboring lymph node areas in an orderly
fashion (Kaplan’s rule) and rarely skips adjacent lymph node
regions. In younger patients, as a rule of thumb, lymph node
areas above the diaphragm are most frequently involved, while
in elderly patients HD lesions tend to cluster below the
diaphragm. The Cotswold staging system for HD is similar to
the Ann Arbor staging used in NHL, with the absence (A) or
presence (B) of constitutional symptoms specified. Prognostic
factors overlap to some extent with those identified in NHL,
with B symptoms, stage, and age being important. A prognostic
score from the German Hodgkin Study Group has identified
a number of additional parameters as being discriminatory,
such as the degree of anemia, low albumin, but (somewhat
surprisingly) not the ESR or LDH.
Treatment of HD offers high chances of cure throughout,
perhaps higher than in any other type of lymphoma. The choice
of treatment depends much on the stage at diagnosis, but no
truly international consensus exists as to the ‘best’ modalities.
Early stage HD with favorable prognostic features may be
treated with radiotherapy alone. Radiotherapy can be given to
clinically/radiologically involved areas (i.e. ‘involved field’) or
extended to include neighboring lymph node areas (i.e.
‘extended field’). Mantle fields more or less involve all lymph
nodes above the diaphragm, while an ‘inverted Y field’
encompasses para-aortic, pelvic, iliacal, and inguinal regions.
Extensive radiotherapy is increasingly being abandoned, and
trends favor short-pulse chemotherapy combined with limited
radiotherapy even for stage I–II patients. In advanced stage, HD
radiation can be limited to tumor bulk with a particularly
high risk of local relapse. In patients with advanced HD stages,
and those at early stages with risk factors, chemotherapy is
mandatory. A number of chemotherapy regimens have been
reported to be active in HD, such as MOPP, ABVD, and their
hybrid combinations, as well as BEACOPP (dose escalated), and
others. Their common denominator is that they combine
alkylating agents, anthracyclines, and steroids. In BEACOPP
and some hybrid regimens, etoposide is added. Optimal
duration and number of cycles are not strictly defined, but for
best results patients generally require several months or up to
half a year of therapy. The combination of extensive
radiotherapy and prolonged administration of alkylating agents
increases the likelihood of secondary AML and solid neoplasms.
Long-term survivors of HD may also suffer from late cardiac
or pulmonary toxicity, or hypothyroidism, which should be
considered at late follow-up visits. Current treatment protocols
are therefore geared not only toward improving cure rates (high
anyway) but also toward limiting such late toxicity. Patients
with HD in relapse may expect a renewed chance of cure, but
they usually require more intensive treatment, and many of
them are candidates for high-dose chemotherapy with
autologous stem-cell transplantation. A minority of patients
experience second or later relapses, and in these chances of cure
tend to dwindle. Palliative treatment may nevertheless be
valuable, but should be cautiously used to limit toxicity. Cure
rates in early stage HD approach 90%–95% of patients. Patients
with far-advanced HD exhibiting adverse prognostic factors
represent the other end of the spectrum, but may still hope for
cure in about 50%.
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